A phase II study of second-line or greater therapy comprising masitinib plus bortezomib [Velcade] in patients with multiple myeloma with t(4/14) translocation and who have relapsed within 12 months after receiving first-line treatment.
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2011
At a glance
- Drugs Bortezomib; Masitinib
- Indications Multiple myeloma
- Focus Pharmacogenomic; Therapeutic Use
- 19 Oct 2011 New trial record
- 17 Oct 2011 Results from this study have been presented in an AB Science media release.